Zaprinast impairs spatial memory by increasing PDE5 expression in the rat hippocampus

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Phosphodiesterase (PDE) inhibitors like zaprinast affect cyclic nucleotide signaling.
• PDE activity and cyclic nucleotide levels vary between brain regions like the striatum and hippocampus.
• Understanding PDE inhibition's role in memory is crucial for cognitive research.

Purpose of the Study:

• To investigate the impact of zaprinast on rat memory retention.
• To explore the role of cyclic nucleotides and PDE activity in zaprinast-induced memory impairment.
• To examine the time-course of these effects and potential rebound phenomena.

Main Methods:

• Post-training intraperitoneal administration of zaprinast in rats.
• Assessment of memory retention using the Morris water maze task.
• Measurement of cyclic nucleotide levels and PDE activity in brain tissues at 30 minutes and 24 hours post-injection.

Main Results:

• Zaprinast administration caused significant memory impairment at a 10mg/kg dose.
• An increase in cyclic nucleotides was observed 30 minutes post-injection, returning to basal levels within 24 hours.
• A significant decrease in hippocampal cyclic guanosine monophosphate (cGMP) was noted at 24 hours post-injection with the 10mg/kg dose, linked to PDE5 induction.

Conclusions:

• Zaprinast's memory impairment effect is dose-dependent.
• A potential rebound effect of PDE inhibitors, specifically PDE5 induction in the hippocampus, may contribute to memory deficits.
• Cyclic nucleotide signaling plays a role in the cognitive effects of PDE inhibitors.